NO328499B1 - Kinuklidyl-N-fenyl-N-alkylkarbamater og anvendelse derav ved fremstilling av medikamenter - Google Patents

Kinuklidyl-N-fenyl-N-alkylkarbamater og anvendelse derav ved fremstilling av medikamenter Download PDF

Info

Publication number: NO328499B1
Authority: NO; Norway
Prior art keywords: quinuclidyl; benzyl; alkyl; group; crc4
Prior art date: 2000-06-27

Application number

NO20026211A

Other languages

English (en)

Norwegian (no)

Other versions

NO20026211D0 (no

NO20026211L (no

Inventor

Andres Fernandez Garcia

Ignacio Jose Miquel Bono

Carmen Lagunas Arnal

Carles Farrerons Gallemi

Juan Lorenzo Catena Ruiz

Anna Fernandez Serrat

Dolors Balsa Lopez

Jose Ignacio Bonilla Navarro

Carolina Salcedo Roca

Original Assignee

Salv At Sa Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-27

Filing date

2002-12-23

Publication date

2010-03-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8494130&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO328499(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-12-23 Application filed by Salv At Sa Lab filed Critical Salv At Sa Lab

2002-12-23 Publication of NO20026211D0 publication Critical patent/NO20026211D0/no

2003-02-26 Publication of NO20026211L publication Critical patent/NO20026211L/no

2010-03-01 Publication of NO328499B1 publication Critical patent/NO328499B1/no

Links

239000003814 drug Substances 0.000 title claims description 9
238000004519 manufacturing process Methods 0.000 title claims description 3
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 13
229910052794 bromium Inorganic materials 0.000 claims abstract description 7
229910052801 chlorine Inorganic materials 0.000 claims abstract description 7
229910052731 fluorine Inorganic materials 0.000 claims abstract description 7
238000011282 treatment Methods 0.000 claims abstract description 7
150000001204 N-oxides Chemical class 0.000 claims abstract description 6
SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical group C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 claims abstract description 6
206010046543 Urinary incontinence Diseases 0.000 claims abstract description 5
229910052740 iodine Inorganic materials 0.000 claims abstract description 5
206010006458 Bronchitis chronic Diseases 0.000 claims abstract description 4
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract description 4
206010014561 Emphysema Diseases 0.000 claims abstract description 4
208000006673 asthma Diseases 0.000 claims abstract description 4
206010006451 bronchitis Diseases 0.000 claims abstract description 4
208000007451 chronic bronchitis Diseases 0.000 claims abstract description 4
208000002551 irritable bowel syndrome Diseases 0.000 claims abstract description 4
208000023504 respiratory system disease Diseases 0.000 claims abstract description 4
206010039083 rhinitis Diseases 0.000 claims abstract description 4
150000001875 compounds Chemical class 0.000 claims description 27
-1 2-benzodioxolanyl Chemical group 0.000 claims description 24
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 14
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
229910052739 hydrogen Inorganic materials 0.000 claims description 8
239000000203 mixture Substances 0.000 claims description 7
229910052757 nitrogen Inorganic materials 0.000 claims description 7
125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 6
125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 6
239000001257 hydrogen Substances 0.000 claims description 6
238000002360 preparation method Methods 0.000 claims description 5
150000003839 salts Chemical class 0.000 claims description 5
210000003932 urinary bladder Anatomy 0.000 claims description 5
125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 4
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 4
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 4
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 4
ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 claims description 4
125000001424 substituent group Chemical group 0.000 claims description 4
201000010099 disease Diseases 0.000 claims description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
RDXICHROOMAYQC-SFYJNAPPSA-M [(3r)-1-methyl-1-azoniabicyclo[2.2.2]octan-3-yl] n-benzyl-n-phenylcarbamate;iodide Chemical compound [I-].O([C@@H]1C2CC[N+](CC2)(C1)C)C(=O)N(C=1C=CC=CC=1)CC1=CC=CC=C1 RDXICHROOMAYQC-SFYJNAPPSA-M 0.000 claims description 2
KZGBMDVPRFXGCT-UHFFFAOYSA-N [3-(1-azabicyclo[2.2.2]octan-2-yl)phenyl]-benzylcarbamic acid hydrochloride Chemical compound Cl.N12C(CC(CC1)CC2)C=2C=C(C=CC2)N(C(O)=O)CC2=CC=CC=C2 KZGBMDVPRFXGCT-UHFFFAOYSA-N 0.000 claims description 2
125000004093 cyano group Chemical group *C#N 0.000 claims description 2
125000005843 halogen group Chemical group 0.000 claims description 2
239000012453 solvate Substances 0.000 claims description 2
ZPDVAXBLZFPQPQ-QNHHWSGXSA-M [(3r)-1-methyl-1-azoniabicyclo[2.2.2]octan-3-yl] n-benzyl-n-(2-fluorophenyl)carbamate;iodide Chemical compound [I-].O([C@@H]1C2CC[N+](CC2)(C1)C)C(=O)N(C=1C(=CC=CC=1)F)CC1=CC=CC=C1 ZPDVAXBLZFPQPQ-QNHHWSGXSA-M 0.000 claims 1
ICYPDFVERJXLOW-RBPPWHDLSA-M [(3r)-1-methyl-1-azoniabicyclo[2.2.2]octan-3-yl] n-benzyl-n-(2-methylphenyl)carbamate;iodide Chemical compound [I-].CC1=CC=CC=C1N(C(=O)O[C@@H]1C2CC[N+](CC2)(C)C1)CC1=CC=CC=C1 ICYPDFVERJXLOW-RBPPWHDLSA-M 0.000 claims 1
150000004657 carbamic acid derivatives Chemical class 0.000 abstract description 9
239000005557 antagonist Substances 0.000 abstract description 5
206010020853 Hypertonic bladder Diseases 0.000 abstract 1
150000001412 amines Chemical class 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
150000003242 quaternary ammonium salts Chemical class 0.000 abstract 1
238000001356 surgical procedure Methods 0.000 abstract 1
102000017925 CHRM3 Human genes 0.000 description 12
101150060249 CHRM3 gene Proteins 0.000 description 12
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
239000002904 solvent Substances 0.000 description 12
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
102000017926 CHRM2 Human genes 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 8
238000000034 method Methods 0.000 description 8
101150012960 Chrm2 gene Proteins 0.000 description 7
102000005962 receptors Human genes 0.000 description 7
108020003175 receptors Proteins 0.000 description 7
230000002829 reductive effect Effects 0.000 description 7
239000007787 solid Substances 0.000 description 7
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
150000003975 aryl alkyl amines Chemical class 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 5
108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 5
FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 5
230000000694 effects Effects 0.000 description 5
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
238000010992 reflux Methods 0.000 description 4
229940126083 M3 antagonist Drugs 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
230000027455 binding Effects 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
239000012043 crude product Substances 0.000 description 3
239000003480 eluent Substances 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000012442 inert solvent Substances 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
239000003921 oil Substances 0.000 description 3
229940044551 receptor antagonist Drugs 0.000 description 3
239000002464 receptor antagonist Substances 0.000 description 3
229910000104 sodium hydride Inorganic materials 0.000 description 3
239000012312 sodium hydride Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
IVLICPVPXWEGCA-ZETCQYMHSA-N (3r)-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C1CC2[C@@H](O)CN1CC2 IVLICPVPXWEGCA-ZETCQYMHSA-N 0.000 description 2
IVLICPVPXWEGCA-UHFFFAOYSA-N 3-quinuclidinol Chemical compound C1C[C@@H]2C(O)C[N@]1CC2 IVLICPVPXWEGCA-UHFFFAOYSA-N 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
229940121948 Muscarinic receptor antagonist Drugs 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 description 2
ATIPBKCFGLKIGH-UHFFFAOYSA-N ethyl n-benzyl-n-phenylcarbamate Chemical compound C=1C=CC=CC=1N(C(=O)OCC)CC1=CC=CC=C1 ATIPBKCFGLKIGH-UHFFFAOYSA-N 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
238000011534 incubation Methods 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
238000006722 reduction reaction Methods 0.000 description 2
210000002460 smooth muscle Anatomy 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 1
DOAKXPDAEYUFEQ-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl carbonochloridate;hydrochloride Chemical compound Cl.C1CC2C(OC(=O)Cl)CN1CC2 DOAKXPDAEYUFEQ-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
229930003347 Atropine Natural products 0.000 description 1
102000017924 CHRM4 Human genes 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 1
230000005526 G1 to G0 transition Effects 0.000 description 1
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
102000007205 Muscarinic M2 Receptor Human genes 0.000 description 1
108010008407 Muscarinic M2 Receptor Proteins 0.000 description 1
208000006550 Mydriasis Diseases 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
208000001871 Tachycardia Diseases 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
101100107916 Xenopus laevis chrm4 gene Proteins 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
125000005210 alkyl ammonium group Chemical group 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
229940051881 anilide analgesics and antipyretics Drugs 0.000 description 1
150000003931 anilides Chemical class 0.000 description 1
150000001448 anilines Chemical class 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
238000003556 assay Methods 0.000 description 1
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
229960000396 atropine Drugs 0.000 description 1
WKFZHVFBHYHYAK-UHFFFAOYSA-N benzyl(phenyl)carbamic acid Chemical compound C=1C=CC=CC=1N(C(=O)O)CC1=CC=CC=C1 WKFZHVFBHYHYAK-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000000621 bronchi Anatomy 0.000 description 1
230000007883 bronchodilation Effects 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
CVXBEEMKQHEXEN-UHFFFAOYSA-N carbaryl Chemical group C1=CC=C2C(OC(=O)NC)=CC=CC2=C1 CVXBEEMKQHEXEN-UHFFFAOYSA-N 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000012230 colorless oil Substances 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000008602 contraction Effects 0.000 description 1
230000001595 contractor effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
HXGBXQDTNZMWGS-RUZDIDTESA-N darifenacin Chemical compound C=1C=CC=CC=1C([C@H]1CN(CCC=2C=C3CCOC3=CC=2)CC1)(C(=O)N)C1=CC=CC=C1 HXGBXQDTNZMWGS-RUZDIDTESA-N 0.000 description 1
229960002677 darifenacin Drugs 0.000 description 1
238000011161 development Methods 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
206010013781 dry mouth Diseases 0.000 description 1
RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
239000006260 foam Substances 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
230000027119 gastric acid secretion Effects 0.000 description 1
230000005176 gastrointestinal motility Effects 0.000 description 1
238000007429 general method Methods 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
230000000762 glandular Effects 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
230000009931 harmful effect Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
238000005567 liquid scintillation counting Methods 0.000 description 1
150000002689 maleic acids Chemical class 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
239000011707 mineral Substances 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000003149 muscarinic antagonist Substances 0.000 description 1
GTWJETSWSUWSEJ-UHFFFAOYSA-N n-benzylaniline Chemical compound C=1C=CC=CC=1CNC1=CC=CC=C1 GTWJETSWSUWSEJ-UHFFFAOYSA-N 0.000 description 1
210000001577 neostriatum Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
229960005434 oxybutynin Drugs 0.000 description 1
230000001734 parasympathetic effect Effects 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
230000001242 postsynaptic effect Effects 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000006268 reductive amination reaction Methods 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
210000003079 salivary gland Anatomy 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
235000019345 sodium thiosulphate Nutrition 0.000 description 1
FBOUYBDGKBSUES-VXKWHMMOSA-N solifenacin Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(O[C@@H]2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-VXKWHMMOSA-N 0.000 description 1
241000894007 species Species 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000006794 tachycardia Effects 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 description 1
229960004045 tolterodine Drugs 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
238000005809 transesterification reaction Methods 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G—PHYSICS
- G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
- G03B—APPARATUS OR ARRANGEMENTS FOR TAKING PHOTOGRAPHS OR FOR PROJECTING OR VIEWING THEM; APPARATUS OR ARRANGEMENTS EMPLOYING ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ACCESSORIES THEREFOR
- G03B27/00—Photographic printing apparatus
- G03B27/02—Exposure apparatus for contact printing
- G—PHYSICS
- G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
- G03B—APPARATUS OR ARRANGEMENTS FOR TAKING PHOTOGRAPHS OR FOR PROJECTING OR VIEWING THEM; APPARATUS OR ARRANGEMENTS EMPLOYING ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ACCESSORIES THEREFOR
- G03B27/00—Photographic printing apparatus
- G03B27/02—Exposure apparatus for contact printing
- G03B27/14—Details
- G03B27/16—Illumination arrangements, e.g. positioning of lamps, positioning of reflectors
- G—PHYSICS
- G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
- G03B—APPARATUS OR ARRANGEMENTS FOR TAKING PHOTOGRAPHS OR FOR PROJECTING OR VIEWING THEM; APPARATUS OR ARRANGEMENTS EMPLOYING ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ACCESSORIES THEREFOR
- G03B27/00—Photographic printing apparatus
- G03B27/02—Exposure apparatus for contact printing
- G03B27/14—Details
- G03B27/30—Details adapted to be combined with processing apparatus
- G03B27/303—Gas processing
- G—PHYSICS
- G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
- G03D—APPARATUS FOR PROCESSING EXPOSED PHOTOGRAPHIC MATERIALS; ACCESSORIES THEREFOR
- G03D13/00—Processing apparatus or accessories therefor, not covered by groups G11B3/00 - G11B11/00
- G03D13/002—Heat development apparatus, e.g. Kalvar

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Physics & Mathematics (AREA)
General Physics & Mathematics (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Otolaryngology (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20026211A 2000-06-27 2002-12-23 Kinuklidyl-N-fenyl-N-alkylkarbamater og anvendelse derav ved fremstilling av medikamenter NO328499B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
ES200001661		2000-06-27
PCT/ES2001/000252 WO2002000652A1 (es)	2000-06-27	2001-06-25	Carbamatos derivados de arilalquilaminas

Publications (3)

Publication Number	Publication Date
NO20026211D0 NO20026211D0 (no)	2002-12-23
NO20026211L NO20026211L (no)	2003-02-26
NO328499B1 true NO328499B1 (no)	2010-03-01

Family

ID=8494130

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20026211A NO328499B1 (no)	2000-06-27	2002-12-23	Kinuklidyl-N-fenyl-N-alkylkarbamater og anvendelse derav ved fremstilling av medikamenter

Country Status (29)

Country	Link
US (2)	US6916828B2 (da)
EP (1)	EP1300407B2 (da)
JP (1)	JP5046465B2 (da)
KR (1)	KR100751981B1 (da)
CN (1)	CN1227251C (da)
AP (1)	AP1420A (da)
AT (1)	ATE260277T1 (da)
AU (2)	AU2001266100B9 (da)
BG (1)	BG66102B1 (da)
BR (1)	BR0112297A (da)
CA (1)	CA2414514C (da)
CR (1)	CR6889A (da)
CZ (1)	CZ294251B6 (da)
DE (2)	DE60102160T3 (da)
DK (1)	DK1300407T4 (da)
EA (1)	EA005520B1 (da)
ES (1)	ES2213703T5 (da)
HU (1)	HU229306B1 (da)
IL (1)	IL153707A0 (da)
MX (1)	MXPA03000141A (da)
NO (1)	NO328499B1 (da)
OA (1)	OA12300A (da)
PL (1)	PL201530B1 (da)
PT (1)	PT1300407E (da)
SI (1)	SI1300407T2 (da)
TR (1)	TR200400420T4 (da)
UA (1)	UA72632C2 (da)
WO (1)	WO2002000652A1 (da)
ZA (1)	ZA200300644B (da)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9913083D0 (en)	1999-06-04	1999-08-04	Novartis Ag	Organic compounds
KR100751981B1 (ko) *	2000-06-27	2007-08-28	라보라토리오스 살바트, 에스.에이.	아릴알킬아민으로부터 유도된 카바메이트
NZ526580A (en)	2000-12-22	2005-04-29	Almirall Prodesfarma Ag	Quinuclidine carbamate derivatives and their use as M3 antagonists
DE60121813T2 (de)	2000-12-28	2007-09-20	Almirall Ag	Neue chinuclidinderivate und medizinische zusammensetzungen, die diese verbindungen enthalten
HUP0501017A3 (en)	2001-12-14	2010-06-28	Targacept	Methods and compositions for treatment of central nervous system disorders
JP4505227B2 (ja) *	2001-12-20	2010-07-21	キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ	１−アルキル−１−アゾニアビシクロ［２．２．２］オクタンカルバメート誘導体およびムスカリンレセプターアンタゴニストとしてのそれらの使用
ES2203327B1 (es) *	2002-06-21	2005-06-16	Almirall Prodesfarma, S.A.	Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es)	2002-07-02	2005-08-01	Almirall Prodesfarma, S.A.	Nuevos derivados de quinuclidina-amida.
AU2002345266B2 (en)	2002-07-08	2009-07-02	Ranbaxy Laboratories Limited	3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
EP1618091A1 (en)	2003-04-09	2006-01-25	Ranbaxy Laboratories, Ltd.	Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
JP2006522787A (ja)	2003-04-11	2006-10-05	ランバクシーラボラトリーズリミテッド	ムスカリン様受容体アンタゴニストとしてのアザビシクロ誘導体
WO2004091597A2 (en) *	2003-04-15	2004-10-28	Pharmacia & Upjohn Company Llc	Method of treating irritable bowel syndrome (ibs)
AR044519A1 (es)	2003-05-02	2005-09-14	Novartis Ag	Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0401334D0 (en)	2004-01-21	2004-02-25	Novartis Ag	Organic compounds
GB0411056D0 (en)	2004-05-18	2004-06-23	Novartis Ag	Organic compounds
ES2246170B1 (es) *	2004-07-29	2007-04-01	Almirall Prodesfarma, S.A.	Nuevo procedimiento para preparar derivados de carbamato de quinuclidinio.
GT200500281A (es)	2004-10-22	2006-04-24	Novartis Ag	Compuestos organicos.
GB0424284D0 (en) *	2004-11-02	2004-12-01	Novartis Ag	Organic compounds
GB0426164D0 (en)	2004-11-29	2004-12-29	Novartis Ag	Organic compounds
GB0507577D0 (en)	2005-04-14	2005-05-18	Novartis Ag	Organic compounds
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
US20090012116A1 (en) *	2005-07-11	2009-01-08	Naresh Kumar	Muscarinic Receptor Antagonists
US7732607B2 (en) *	2005-08-22	2010-06-08	Anatoly Mazurov	Heteroaryl-substituted diazatricycloalkanes and methods of use thereof
AU2006305619A1 (en)	2005-10-19	2007-04-26	Ranbaxy Laboratories Limited	Pharmaceutical compositions of muscarinic receptor antagonists
WO2007045477A2 (en)	2005-10-21	2007-04-26	Novartis Ag	Human antibodies against il-13 and therapeutic uses
GB0601951D0 (en)	2006-01-31	2006-03-15	Novartis Ag	Organic compounds
PT2322525E (pt)	2006-04-21	2013-12-26	Novartis Ag	Derivados de purina para utilização como agonistas do recetor de adenosina a2a
EP1882691A1 (en) *	2006-07-26	2008-01-30	CHIESI FARMACEUTICI S.p.A.	Quinuclidine derivatives as M3 antagonists
WO2008037477A1 (en)	2006-09-29	2008-04-03	Novartis Ag	Pyrazolopyrimidines as p13k lipid kinase inhibitors
RS51644B (sr)	2007-01-10	2011-10-31	Irm Llc.	Jedinjenja i preparati kao inhibitori kanal aktivirajuće proteaze
EP2119716A4 (en)	2007-02-09	2011-06-01	Astellas Pharma Inc	AZA BRIDGE CYCLE COMPOUND
CN101687851B (zh)	2007-05-07	2013-02-27	诺瓦提斯公司	有机化合物
SA08290475B1 (ar)	2007-08-02	2013-06-22	Targacept Inc	(2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
WO2009046025A1 (en) *	2007-10-01	2009-04-09	Comentis, Inc.	Quinuclidin-4-ylmethyl 1h-indole-3-carboxylate derivatives as alpha 7 nicotinic acetylcholine receptor ligands for the treatment of alzheimer's disease
EP2065385A1 (en) *	2007-11-28	2009-06-03	Laboratorios SALVAT, S.A.	Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester
CL2008003651A1 (es)	2007-12-10	2009-06-19	Novartis Ag	Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias.
AU2009203693B2 (en)	2008-01-11	2012-06-07	Novartis Ag	Pyrimidines as kinase inhibitors
KR20100113163A (ko) *	2008-02-13	2010-10-20	타가셉트 인코포레이티드	알파 ７ 니코틴 작용제 및 항정신병제의 조합
US8268834B2 (en)	2008-03-19	2012-09-18	Novartis Ag	Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
CA2727196A1 (en)	2008-06-10	2009-12-17	Novartis Ag	Organic compounds
TW201031664A (en)	2009-01-26	2010-09-01	Targacept Inc	Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
PL2391366T3 (pl)	2009-01-29	2013-04-30	Novartis Ag	Podstawione benzimidazole do leczenia gwiaździaków
US8389526B2 (en)	2009-08-07	2013-03-05	Novartis Ag	3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru)	2009-08-12	2012-09-28	Новартис Аг	Гетероциклические гидразоны и их применение для лечения рака и воспаления
NZ598220A (en)	2009-08-17	2014-02-28	Intellikine Llc	Heterocyclic compounds and uses thereof
CA2771432A1 (en)	2009-08-20	2011-02-24	Novartis Ag	Heterocyclic oxime compounds
US20110098311A1 (en)	2009-10-22	2011-04-28	Vertex Pharmaceuticals Incorported	Compositions for treatment of cystic fibrosis and other chronic diseases
US8247436B2 (en)	2010-03-19	2012-08-21	Novartis Ag	Pyridine and pyrazine derivative for the treatment of CF
WO2011137054A1 (en)	2010-04-30	2011-11-03	Merck Sharp & Dohme Corp.	Novel beta 3 adrenergic receptor agonists
UY33597A (es)	2010-09-09	2012-04-30	Irm Llc	Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en)	2010-09-09	2012-03-15	Irm Llc	Compounds and compositions as trk inhibitors
US8372845B2 (en)	2010-09-17	2013-02-12	Novartis Ag	Pyrazine derivatives as enac blockers
EP2673277A1 (en)	2011-02-10	2013-12-18	Novartis AG	[1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en)	2011-02-23	2012-08-30	Intellikine, Llc	Heterocyclic compounds and uses thereof
MA34969B1 (fr)	2011-02-25	2014-03-01	Irm Llc	Composes et compositions en tant qu inibiteurs de trk
US8883819B2 (en)	2011-09-01	2014-11-11	Irm Llc	Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
CA2848809A1 (en)	2011-09-15	2013-03-21	Novartis Ag	6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase
WO2013038381A1 (en)	2011-09-16	2013-03-21	Novartis Ag	Pyridine/pyrazine amide derivatives
ES2882807T3 (es)	2011-09-16	2021-12-02	Novartis Ag	Heterociclil carboxamidas N-sustituidas
WO2013038386A1 (en)	2011-09-16	2013-03-21	Novartis Ag	Heterocyclic compounds for the treatment of cystic fibrosis
WO2013038373A1 (en)	2011-09-16	2013-03-21	Novartis Ag	Pyridine amide derivatives
WO2013038378A1 (en)	2011-09-16	2013-03-21	Novartis Ag	Pyridine amide derivatives
JP6130391B2 (ja)	2011-11-23	2017-05-17	インテリカイン，エルエルシー	Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
US8809340B2 (en)	2012-03-19	2014-08-19	Novartis Ag	Crystalline form
AU2013243097A1 (en)	2012-04-03	2014-10-09	Novartis Ag	Combination products with tyrosine kinase inhibitors and their use
MA37975B2 (fr)	2012-09-11	2021-03-31	Genzyme Corp	Inhibiteurs de synthase de glucosylcéramide
US9073921B2 (en)	2013-03-01	2015-07-07	Novartis Ag	Salt forms of bicyclic heterocyclic derivatives
EP2968340A4 (en)	2013-03-15	2016-08-10	Intellikine Llc	COMBINING KINASE INHIBITORS AND USES THEREOF
JP6218940B2 (ja) *	2013-07-13	2017-10-25	ベイジンエフエスウェルカムテクノロジーディベロップメントカンパニーリミテッド	キニン系化合物、その光学異性体及びその製造方法と医薬用途
TW201605450A (zh)	2013-12-03	2016-02-16	諾華公司	Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
KR102736869B1 (ko)	2014-03-07	2024-12-02	바이오크리스트파마슈티컬즈,인코포레이티드	인간 혈장 칼리크레인 저해제
CA2945212A1 (en)	2014-04-24	2015-10-29	Novartis Ag	Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
BR112016024484A2 (pt)	2014-04-24	2017-08-15	Novartis Ag	derivados de aminopiridina como inibidores de fosfatidilinositol 3-quinase
US9862711B2 (en)	2014-04-24	2018-01-09	Novartis Ag	Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
JP2017524736A (ja)	2014-07-11	2017-08-31	アルファーマゲン，エルエルシー	アルファ７−ニコチン性アセチルコリン受容体活性を調節するためのキヌクリジン化合物
WO2016011658A1 (en)	2014-07-25	2016-01-28	Novartis Ag	Combination therapy
CA2954862A1 (en)	2014-07-31	2016-02-04	Novartis Ag	Combination therapy
US9724340B2 (en)	2015-07-31	2017-08-08	Attenua, Inc.	Antitussive compositions and methods
CA3102279A1 (en)	2018-06-01	2019-12-05	Cornell University	Combination therapy for pi3k-associated disease or disorder
CN114040762A (zh)	2019-02-04	2022-02-11	建新公司	使用葡糖神经酰胺合酶(gcs)的抑制剂治疗纤毛疾病
AU2020290094B2 (en)	2019-06-10	2024-01-18	Novartis Ag	Pyridine and pyrazine derivative for the treatment of CF, COPD, and bronchiectasis
AU2020338971B2 (en)	2019-08-28	2023-11-23	Novartis Ag	Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
TW202140550A (zh)	2020-01-29	2021-11-01	瑞士商諾華公司	使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
JP2023512366A (ja)	2020-02-03	2023-03-27	ジェンザイム・コーポレーション	リソソーム蓄積性疾患と関連する神経学的症状を処置するための方法
AU2021311131B2 (en)	2020-07-24	2026-02-19	Genzyme Corporation	Pharmaceutical compositions comprising venglustat

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3287471A (en)	1964-05-05	1966-11-22	Searle & Co	Pyrrolidinyl nu-phenyl-nu-benzylcarbamates
JPH0495071A (ja)	1990-08-10	1992-03-27	Kyorin Pharmaceut Co Ltd	カルバミン酸誘導体
WO1995006635A1 (en) *	1993-09-02	1995-03-09	Yamanouchi Pharmaceutical Co., Ltd.	Carbamate derivative and medicine containing the same
AU685225B2 (en) *	1994-02-10	1998-01-15	Yamanouchi Pharmaceutical Co., Ltd.	Novel carbamate derivative and medicinal composition containing the same
NO2005012I1 (no) *	1994-12-28	2005-06-06	Debio Rech Pharma Sa	Triptorelin og farmasoytisk akseptable salter derav
JPH08198751A (ja) *	1995-01-19	1996-08-06	Yamanouchi Pharmaceut Co Ltd	カルバメート誘導体
KR100751981B1 (ko) *	2000-06-27	2007-08-28	라보라토리오스 살바트, 에스.에이.	아릴알킬아민으로부터 유도된 카바메이트
NZ526580A (en) *	2000-12-22	2005-04-29	Almirall Prodesfarma Ag	Quinuclidine carbamate derivatives and their use as M3 antagonists
JP4505227B2 (ja) *	2001-12-20	2010-07-21	キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ	１−アルキル−１−アゾニアビシクロ［２．２．２］オクタンカルバメート誘導体およびムスカリンレセプターアンタゴニストとしてのそれらの使用

2001
- 2001-06-25 KR KR1020027017706A patent/KR100751981B1/ko not_active Expired - Fee Related
- 2001-06-25 DK DK01943553.6T patent/DK1300407T4/da active
- 2001-06-25 HU HU0301414A patent/HU229306B1/hu not_active IP Right Cessation
- 2001-06-25 AU AU2001266100A patent/AU2001266100B9/en not_active Ceased
- 2001-06-25 EP EP01943553A patent/EP1300407B2/en not_active Expired - Lifetime
- 2001-06-25 IL IL15370701A patent/IL153707A0/xx not_active IP Right Cessation
- 2001-06-25 US US10/312,227 patent/US6916828B2/en not_active Expired - Fee Related
- 2001-06-25 JP JP2002505776A patent/JP5046465B2/ja not_active Expired - Fee Related
- 2001-06-25 CZ CZ2003261A patent/CZ294251B6/cs not_active IP Right Cessation
- 2001-06-25 CN CNB018148042A patent/CN1227251C/zh not_active Expired - Fee Related
- 2001-06-25 OA OA1200200393A patent/OA12300A/en unknown
- 2001-06-25 BR BR0112297-5A patent/BR0112297A/pt active Search and Examination
- 2001-06-25 AT AT01943553T patent/ATE260277T1/de active
- 2001-06-25 AP APAP/P/2003/002722A patent/AP1420A/en active
- 2001-06-25 AU AU6610001A patent/AU6610001A/xx not_active Withdrawn
- 2001-06-25 WO PCT/ES2001/000252 patent/WO2002000652A1/es not_active Ceased
- 2001-06-25 MX MXPA03000141A patent/MXPA03000141A/es active IP Right Grant
- 2001-06-25 SI SI200130075T patent/SI1300407T2/sl unknown
- 2001-06-25 CA CA002414514A patent/CA2414514C/en not_active Expired - Fee Related
- 2001-06-25 ES ES01943553T patent/ES2213703T5/es not_active Expired - Lifetime
- 2001-06-25 DE DE60102160T patent/DE60102160T3/de not_active Expired - Lifetime
- 2001-06-25 TR TR2004/00420T patent/TR200400420T4/xx unknown
- 2001-06-25 EA EA200300072A patent/EA005520B1/ru not_active IP Right Cessation
- 2001-06-25 DE DE20122417U patent/DE20122417U1/de not_active Expired - Lifetime
- 2001-06-25 PL PL359333A patent/PL201530B1/pl unknown
- 2001-06-25 PT PT01943553T patent/PT1300407E/pt unknown
- 2001-06-25 UA UA2003010718A patent/UA72632C2/uk unknown
2002
- 2002-12-23 NO NO20026211A patent/NO328499B1/no not_active IP Right Cessation
2003
- 2003-01-17 BG BG107474A patent/BG66102B1/bg unknown
- 2003-01-20 CR CR6889A patent/CR6889A/es not_active Application Discontinuation
- 2003-01-23 ZA ZA200300644A patent/ZA200300644B/en unknown
2004
- 2004-06-23 US US10/875,592 patent/US7115629B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AU6610001A (en)	2002-01-08
PL201530B1 (pl)	2009-04-30
BG66102B1 (bg)	2011-04-29
US20040063950A1 (en)	2004-04-01
US7115629B2 (en)	2006-10-03
AP1420A (en)	2005-05-30
JP5046465B2 (ja)	2012-10-10
EP1300407B2 (en)	2011-06-08
HU229306B1 (en)	2013-10-28
ZA200300644B (en)	2004-02-10
EA005520B1 (ru)	2005-04-28
BG107474A (en)	2003-09-30
CA2414514A1 (en)	2002-01-03
AU2001266100B9 (en)	2005-10-06
SI1300407T1 (en)	2004-06-30
KR20030022159A (ko)	2003-03-15
CZ2003261A3 (cs)	2003-06-18
SI1300407T2 (sl)	2011-09-30
BR0112297A (pt)	2003-05-06
AU2001266100B2 (en)	2005-06-30
HUP0301414A3 (en)	2008-03-28
CN1227251C (zh)	2005-11-16
ATE260277T1 (de)	2004-03-15
US6916828B2 (en)	2005-07-12
IL153707A0 (en)	2003-07-06
CA2414514C (en)	2009-12-22
CR6889A (es)	2008-08-21
CZ294251B6 (cs)	2004-11-10
OA12300A (en)	2006-05-12
PL359333A1 (en)	2004-08-23
JP2004501916A (ja)	2004-01-22
DE60102160T3 (de)	2012-05-03
HK1054934A1 (en)	2003-12-19
DK1300407T3 (da)	2004-03-22
EA200300072A1 (ru)	2003-06-26
NO20026211D0 (no)	2002-12-23
MXPA03000141A (es)	2003-05-27
UA72632C2 (uk)	2005-03-15
DE60102160T2 (de)	2004-09-09
DE60102160D1 (de)	2004-04-01
KR100751981B1 (ko)	2007-08-28
DK1300407T4 (da)	2011-09-05
HUP0301414A2 (hu)	2003-09-29
WO2002000652A1 (es)	2002-01-03
ES2213703T3 (es)	2004-09-01
NO20026211L (no)	2003-02-26
PT1300407E (pt)	2004-05-31
DE20122417U1 (de)	2005-08-04
EP1300407B1 (en)	2004-02-25
AP2003002722A0 (en)	2003-06-30
ES2213703T5 (es)	2011-11-02
EP1300407A1 (en)	2003-04-09
US20040235887A1 (en)	2004-11-25
CN1449396A (zh)	2003-10-15
TR200400420T4 (tr)	2004-03-22

Legal Events

Date	Code	Title	Description
2017-01-30	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO328499B1 (no)	2010-03-01	Kinuklidyl-N-fenyl-N-alkylkarbamater og anvendelse derav ved fremstilling av medikamenter
US5929089A (en)	1999-07-27	5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3H)-one derivatives for use as 5-Ht4 or H3 receptor ligands
NO318026B1 (no)	2005-01-24	Kinuklidinderivat og farmasoytisk preparat
IE921364A1 (en)	1992-11-04	Polycyclic amine compounds and their enantiomers, their¹method of preparation and pharmaceutical compositions in¹which they are present
EP0377967A2 (en)	1990-07-18	9-Aza-3-(oxa/thia)-bicyclo[3,2,1]nonane derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them
KR20110034020A (ko)	2011-04-04	알킬 티아졸 카르바메이트 유도체, 그의 제조법, 및 ｆａａｈ 효소 억제제로서의 그의 용도
EP0289170A2 (en)	1988-11-02	Azabicyclic compounds, process for their preparation and pharmaceutical compositions containing them
ME02212B (me)	2016-02-20	Nova jedinjenja kao ligandi histamin h3 receptora
EP1940823A2 (fr)	2008-07-09	Dérivés de la 1-amino-phtalazine substituee, leur préparation et leur application en thérapeutique
KR20190062081A (ko)	2019-06-05	Jak 저해제 화합물, 및 이의 제조방법
KR20150068960A (ko)	2015-06-22	치환된 카바메이트 화합물 및 일시적 수용체 전위(trp) 채널 길항제로서의 이의 용도
CZ280931B6 (cs)	1996-05-15	Opticky aktivní karboxamidové deriváty, farmaceutický prostředek s analgetickým účinkem a prostředek s agonistickým účinkem vzhledem ke k-receptorům
US11376258B2 (en)	2022-07-05	Purine derivatives and the use thereof as medicament
HK1054934B (en)	2004-10-21	Carbamates derived from arylalkylamines
WO1995025100A1 (fr)	1995-09-21	Utilisation d'esters de l'acide 4-amino-5-chloro-2-methoxybenzoique comme 5-ht4 agonistes
WO2006005980A1 (en)	2006-01-19	Xanthine derivatives useful as muscarinic receptor antagonists
JPWO1995026953A1 (ja)	1996-09-24	安息香酸化合物およびその医薬としての用途